Chettri Subhash, Bhat B Vishnu, Adhisivam B
Department of Neonatology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, 605 006, India.
Indian J Pediatr. 2016 Oct;83(10):1125-30. doi: 10.1007/s12098-016-2128-9. Epub 2016 May 21.
In developing countries, meconium aspiration syndrome (MAS) is an important cause of morbidity and mortality among neonates. The concepts of pathophysiology and management of meconium stained amniotic fluid (MSAF) and meconium aspiration syndrome have undergone tremendous change in recent years. Routine intranatal and postnatal endotracheal suctioning of meconium in vigorous infants is no longer recommended. Recent studies have challenged its role even in non-vigorous infants. Supportive therapy like oxygen supplementation, mechanical ventilation and intravenous fluids are the cornerstone in the management of meconium aspiration syndrome. Availability of surfactant, inhaled nitric oxide, high frequency ventilators and extracorporeal membrane oxygenation has made it possible to salvage more infants with meconium aspiration syndrome. In this review the authors have discussed the current concepts in the pathophysiology and management of MAS. Drugs in trials and future therapeutic targets are also discussed briefly.
在发展中国家,胎粪吸入综合征(MAS)是新生儿发病和死亡的重要原因。近年来,胎粪污染羊水(MSAF)和胎粪吸入综合征的病理生理学及管理概念发生了巨大变化。不再推荐对活力良好的婴儿在产前和产后常规进行气管内吸引胎粪。最近的研究甚至对其在非活力良好婴儿中的作用提出了质疑。补充氧气、机械通气和静脉输液等支持性治疗是胎粪吸入综合征管理的基石。表面活性剂、吸入一氧化氮、高频通气机和体外膜肺氧合的应用使得挽救更多患有胎粪吸入综合征的婴儿成为可能。在这篇综述中,作者讨论了胎粪吸入综合征病理生理学和管理的当前概念。还简要讨论了正在试验的药物和未来的治疗靶点。